Kōichi Goto

24.2k citations

497 papers · 10.8k indexed · 5 hit papers · h-index 50

Oncology top 0.2%
- Lung Cancer Research Studies 136
- Colorectal Cancer Treatments and Studies 68
- Cancer Immunotherapy and Biomarkers 31
Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 289
- Lung Cancer Diagnosis and Treatment 100
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 56
Molecular Biology top 2%
- Cancer therapeutics and mechanisms 34
Pathology and Forensic Medicine top 2%
Epidemiology
- Neuroendocrine Tumor Research Advances 35

Co-authors: Kiyotaka Yoh Seiji Niho Genichiro Ishii Shingo Matsumoto Yutaka Nishiwaki Hironobu Ohmatsu Yuichiro Ohe Takashi Seto
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Partner nations: Japan United States South Korea

In The Last Decade

Kōichi Goto

475 papers receiving 10.6k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
2020 TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
2018 Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
2017 Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
2014 Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Peers

Countries citing papers authored by Kōichi Goto

Since Specialization

Citations

This map shows the geographic impact of Kōichi Goto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kōichi Goto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kōichi Goto more than expected).

Fields of papers citing papers by Kōichi Goto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kōichi Goto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kōichi Goto. The network helps show where Kōichi Goto may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kōichi Goto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kōichi Goto Line = papers co-authored together Kōichi Goto links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) Alexander I. Spira,Byoung Chul Cho,Enriqueta Felip,Edward B. Garon,Kōichi Goto,Melissa Johnson,Natasha B. Leighl,Antonio Passaro,David Planchard,Sanjay Popat,James Chih‐Hsin Yang,Xiaoqian Lu,Yong Jiang,Jack Huang,Morgan Lam,Marcin Kowanetz,Shirley Wang,John T. Le,Jerry Y. Hsu,Caicun Zhou	2024	0
2	1395TiP A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02) A. Passaro,Jan C. Brase,Jing Xu,Lidia Mongay Soler,Kōichi Goto	2024	2
3	Nurse‐Led Screening‐Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial Yoshihisa Matsumoto,Shigeki Umemura,Ayumi Okizaki,Daisuke Fujisawa,Takuhiro Yamaguchi,Shunsuke Oyamada,Tempei Miyaji,Tomoe Mashiko,Naoko Kobayashi,Eriko Satomi,Daisuke Kiuchi,Tatsuya Morita,Yosuke Uchitomi,Kōichi Goto,Yuichiro Ohe	2024	1
4	515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates H. Horinouchi,B.C. Cho,D.R. Camidge,Kōichi Goto,P. Tomasini,Y. Li,Athanasios Vasilopoulos,Priya Brunsdon,D. Hoffman,Wenyin Shi,Vincent Blot,J.W. Goldman	2023	7
5	Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial Tsuneo Shimokawa,Hiroaki Okamoto,Ryunosuke Machida,Yuki Misumi,Yukio Hosomi,Yasuto Yoneshima,Hiroshi Tanaka,Kyoichi Okishio,Junichi Simizu,Kōichi Goto,Hiroaki Akamatsu,Kaoru Kubota,Kazuhiko Nakagawa,Hidehito Horinouchi,Masahiko Ando,Tomoko Kataoka,Yuichiro Ohe	2023	4
6	510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02) Yasushi Goto,Kōichi Goto,Toshio Kubo,Kiichiro Ninomiya,S-W. Kim,M-J. Ahn,Kazuhiko Nakagawa,Hidetoshi Hayashi,Junichi Shimizu,Dongwook Kim,J.C-H. Yang,C-H.S. Kuo,K.H. Lee,T-Y. Yang,Kaline Pereira,Ayumi Taguchi,Ahmed Ali,F-C. Cheng,Rie Yonemochi,Pasi A. Jänne	2023	2
7	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 Pasi A. Jänne,Yasushi Goto,Toshio Kubo,Kiichiro Ninomiya,S.-W. Kim,D. Planchard,Myung‐Ju Ahn,Egbert F. Smit,Adrianus J. de Langen,M. Pérol,E. Pons-Tostivint,Silvia Novello,Hidetoshi Hayashi,Junichi Shimizu,D.-W. Kim,Karla Pereira,Fang Cheng,Ayumi Taguchi,Yun Cheng,Kōichi Goto	2023	2
8	1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088 Herbert H. Loong,Gennaro Daniele,T-Y. Yang,Ticiana Leal,Kōichi Goto,Yuki Shinno,Kazumi Nishino,Tomohiro Sakamoto,Enriqueta Felip,J.C. Ruffinelli,Natalia Gallot,Zhou Wang,Chen Chen,Barbara J. Brennan,S-F. Pu,Martin Kornacker,Paolo Grassi,Xiuning Le,Daniel Shao-Weng Tan,B-C. Goh	2023	4
9	1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) Alison M. Schram,Kōichi Goto,Dongwook Kim,Antoine Hollebecque,Sun Young Rha,Kazumi Nishino,M. Duruisseaux,K. Umemoto,Joon Oh Park,Natasha B. Leighl,Teresa Macarulla,Stephen V. Liu,Mohammed Najeeb Al Hallak,James M. Cleary,Cindy Neuzillet,Yasushi Goto,Andrew K. Joe,Shola Adeyemi,Shekeab Jauhari,Alexander Drilon	2023	10
10	Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial Tatsuya Yoshida,Toru Kumagai,Ryo Toyozawa,Ryohei Katayama,Makoto Nishio,Takashi Seto,Kōichi Goto,Nobuyuki Yamamoto,Yuichiro Ohe,Kentarou Kudou,Takayuki Asato,Pingkuan Zhang,Kazuhiko Nakagawa	2023	7
11	Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience Atsushi Ohtsu,Kōichi Goto,Takayuki Yoshino	2023	3
12	Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trialbreakdown → Alexander Drilon,Vivek Subbiah,Oliver Gautschi,Pascale Tomasini,Filippo de Braud,Benjamin Solomon,Daniel S.W. Tan,Guzmán Alonso,Jürgen Wolf,Keunchil Park,Kōichi Goto,Victoria Soldatenkova,Sylwia Szymczak,Scott Barker,Tarun Puri,Aimee Bence Lin,Herbert H. Loong,Benjamin Besse	2022	119
13	Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy Shoko Noda‐Narita,Tomoyuki Naito,Hibiki Udagawa,Kōichi Goto,Taichi Miyawaki,Nobuaki Mamesaya,Kazuhisa Nakashima,Hirotsugu Kenmotsu,Tadasuke Shimokawaji,Terufumi Kato,Taiki Hakozaki,Yusuke Okuma,Masaki Nakamura,Yuko Nakayama,Hirokazu Watanabe,Masahiko Kusumoto,Yuichiro Ohe,Hidehito Horinouchi	2022	6
14	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Yukie Kashima,Daisuke Shibahara,Ayako Suzuki,Kyoko Muto,Ikei S. Kobayashi,David Plotnick,Hibiki Udagawa,Hiroki Izumi,Yuji Shibata,Kosuke Tanaka,Masanori Fujii,Akihiro Ohashi,Masahide Seki,Kōichi Goto,Katsuya Tsuchihara,Yutaka Suzuki,Susumu Kobayashi	2021	49
15	Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Kōichi Goto,Seiji Yano	2020	38
16	TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations Hibiki Udagawa,Shinichi Hasako,Akihiro Ohashi,Rumi Fujioka,Yumi Hakozaki,Mikiko Shibuya,Naomi Abe,Toshiharu Komori,Tomonori Haruma,Miki Terasaka,Ryoto Fujita,Akihiro Hashimoto,Kaoru Funabashi,Hiroyuki Yasuda,Kazutaka Miyadera,Kōichi Goto,Daniel B. Costa,Susumu Kobayashi	2019	55
17	Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma Hideki Makinoshima,Shigeki Umemura,Ayako Suzuki,Hiroki Nakanishi,Ami Maruyama,Hibiki Udagawa,Sachiyo Mimaki,Shingo Matsumoto,Seiji Niho,Genichiro Ishii,Masahiro Tsuboi,Atsushi Ochiai,Hiroyasu Esumi,Takehiko Sasaki,Kōichi Goto,Katsuya Tsuchihara	2018	33
18	Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors Shigenari Nukaga,Hiroyuki Yasuda,Katsuya Tsuchihara,Junko Hamamoto,Keita Masuzawa,Ichiro Kawada,Katsuhiko Naoki,Shingo Matsumoto,Sachiyo Mimaki,Shinnosuke Ikemura,Kōichi Goto,Tomoko Betsuyaku,Kenzo Soejima	2017	131
19	Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung Tomohiro Miyoshi,Shigeki Umemura,Yuki Matsumura,Sachiyo Mimaki,Satoshi Tada,Hideki Makinoshima,Genichiro Ishii,Hibiki Udagawa,Shingo Matsumoto,Kiyotaka Yoh,Seiji Niho,Hironobu Ohmatsu,Keiju Aokage,Tomoyuki Hishida,Junji Yoshida,Kanji Nagai,Kōichi Goto,Masahiro Tsuboi,Katsuya Tsuchihara	2016	139
20	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation Tatsuya Yoshida,Genichiro Ishii,Kōichi Goto,Shinya Neri,Hiroko Hashimoto,Kiyotaka Yoh,Seiji Niho,Shigeki Umemura,Shingo Matsumoto,Hironobu Ohmatsu,Shinsuke Iida,Akio Niimi,Kanji Nagai,Yuichiro Ohe,Atsushi Ochiai	2014	102

About Kōichi Goto

Kōichi Goto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 497 papers that have together received 10.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (289 papers), Lung Cancer Research Studies (136 papers), Lung Cancer Diagnosis and Treatment (100 papers), Colorectal Cancer Treatments and Studies (68 papers), Cancer Genomics and Diagnostics (56 papers), Neuroendocrine Tumor Research Advances (35 papers), Cancer therapeutics and mechanisms (34 papers) and Cancer Immunotherapy and Biomarkers (31 papers). The work is most often cited by research in Oncology (6.6k citations), Pulmonary and Respiratory Medicine (6.4k citations) and Cancer Research (1.9k citations). Kōichi Goto has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Kiyotaka Yoh, Seiji Niho, Genichiro Ishii, Shingo Matsumoto, Yutaka Nishiwaki, Hironobu Ohmatsu, Yuichiro Ohe, Takashi Seto, Nobuyuki Yamamoto and Makoto Nishio.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact